Piramal signs PET agent deal with Ci-Co Healthcare

AuntMinnie.com staff writers
Nov 20, 2013

Piramal Imaging has entered into a strategic partnership with Ci-Co Healthcare.

The deal includes an exclusive licensing agreement for Ci-Co Healthcare to obtain market authorization from the Korean Health Authorities and commercialize Piramal's PET amyloid imaging agent F-18 florbetaben in South Korea.

Ci-Co has assigned the manufacturing and supply of the agent to DuChemBio, a radiopharmacy network in South Korea.

Latest in Nuclear Medicine
Kidneys
Kidneys appear to tolerate Lu-177 treatments
December 19, 2024
Theranostics for neuroendocrine tumors: Glenda’s journey
Sponsored
Theranostics for neuroendocrine tumors: Glenda’s journey
December 1, 2024
2024 10 28 Meningioma Thumbnail
Intraarterial PRRT safe in patients with meningioma
October 28, 2024
Mo 99
NNSA's Mo-99 program: A bumpy ride
October 10, 2024
Related Stories
2012 09 10 09 25 16 46 Mol Insider Piramal Florbetaben Pet Images Thumb
Molecular Imaging
Piramal moves ahead with florbetaben PET for Alzheimer's
2013 09 06 11 46 32 375 Fda Logo 200
Nuclear Medicine
FDA warns of risks with Lexiscan, Adenoscan stress agents
2013 11 15 12 54 38 523 2013 11 18 Molecular Thumb
Nuclear Medicine
PiB-PET shows more beta amyloid after traumatic brain injury
Theranostics for neuroendocrine tumors: Glenda’s journey
Sponsor Content
Theranostics for neuroendocrine tumors: Glenda’s journey
More in Nuclear Medicine
Kidneys appear to tolerate Lu-177 treatments
By Will Morton
Kidney-absorbed doses of lutetium-177 (Lu-177)-based treatments for prostate cancer and neuroendocrine tumors appear to be below toxicity thresholds.
December 19, 2024
Kidneys
African American men respond more favorably to Ra-223 therapy
By Will Morton
African American men with metastatic castrate-resistant prostate cancer may respond more favorably than white men to treatment with radium-223.
December 17, 2024
Prostate Imaging
Intraarterial PRRT safe in patients with meningioma
By Will Morton
Intraarterial peptide receptor radionuclide therapy (PRRT) is a safe and effective alternative to intravenous PRRT in patients with advanced meningioma.
October 28, 2024
2024 10 28 Meningioma Thumbnail
NNSA's Mo-99 program: A bumpy ride
By Will Morton
Last year was a bumpy ride for a U.S. initiative to secure domestic supplies of molybdenum-99 (Mo-99).
October 10, 2024
Mo 99
How effective is Pluvicto in a ‘real-world’ setting?
By Will Morton
Pluvicto appears to perform as effectively in prostate cancer patients in “real-world” settings as it did in clinical trials prior to its approval.
September 20, 2024
Prostate
SNMMI: PET-based protocol shows promise in radioligand therapy
By Amerigo Allegretto
A PET-based scout dosimetry protocol can be feasible in treating lesions with yttrium-90 FAPI (Y-90 FAPI) radioligand therapy.
June 12, 2024
Lesion uptake from a patient with a solitary fibrous tumor and its FAP expression on gallium-68 (GA-68)-FAPI-46 (A) and intratherpeutic Y-90-FAPI-46 (B). The panel shows the constructed time activity curve with the three PET/CT measurements.
The rise of theranostics: Part 3 -- What is a theranostics center?
By Liz Carey
For this third in a series covering the rise of theranostics, AuntMinnie.com asked four doctors of theranostics to discuss the spectrum of freestanding theranostics center development.
June 3, 2024
Part3 Riseof Thernaostics Cover
Can AI improve sustainability in nuclear medicine?
Nuclear medicine experts support the use of AI to improve sustainability of practices in the field, yet say implementation will require careful consideration of the technology’s benefits and detriments.
April 9, 2024
ChatGPT powered by GPT-4 and using DALL-E−3 was asked to generate an image for teaching purposes that demonstrated: a nuclear medicine bone scan with skeletal metastases (top left); coronary artery disease (top right); an F-18 FDG-PET scan of the brain with Alzheimer's disease (bottom left); and an x-ray showing a fracture (bottom right). These are misleading for educational purposes and for patients who may be searching for information. Image and caption courtesy of Radiography.
The rise of theranostics: Part 2 -- Moving into communities
By Liz Carey
In part 2 of The Rise of theranostics series, experts weigh in on getting started in prostate cancer theranostics as some private urology, radiation oncology practices, and radiologist groups begin building their abilities.
April 4, 2024
Theranostics with Thomas Hope, MD, University of California, San Francisco (UCSF)
SNMMI to tackle Capitol Hill
By AuntMinnie.com staff writers
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) will host its annual Hill Day on April 5 in Washington, DC.
April 3, 2024
Us Flag
The rise of theranostics: Part 1 -- Gaining momentum
By Liz Carey
FDA-approved radiopharmaceuticals have energized the field of theranostics. In part 1 of a series, experienced theranostics leaders offer implications of the latest clinical trials, how a theranostics clinic works, and advice for introducing theranostics.
March 19, 2024
Team members from the theranostics clinic under University of Texas Health Science Center at San Antonio's Department of Radiology show one aspect of a Pluvicto infusion treatment. The L block lead shield over the syringe helps protect certified nuclear medicine technologist James Johnson (left), and nuclear radiologist Penny Vroman, MD (right), from radiation emitted by the drug. (Photo courtesy of UT Health San Antonio Department of Radiology)
Cannabis may influence bowel motility
By Will Morton
Physicians, health care providers, and medical staff caring for patients who use cannabis should be familiar with the effects of the drug on gut motility, a recent report advises.
March 11, 2024
Cannabis
Page 1 of 436
Next Page